Saxenda®

DRUG3 trials

Sponsors

Texas Tech University, Boehringer Ingelheim, Novo Nordisk A/S

Conditions

HealthyObesityObesity or Overweight

Phase 1

A Study in Men With Overweight to Test How Well Different Doses of BI 1820237 Are Tolerated When Given as an Injection Alone or in Combination With Liraglutide

CompletedNCT04903509

Boehringer IngelheimHealthy

Start: 2021-06-08End: 2022-08-26Updated: 2022-08-31

Unknown Phase

To Predict Weight Loss Response to Liraglutide (Saxenda®), From fMRI-based Determination of Food Cue Reactivity

CompletedNCT03795701

Texas Tech UniversityObesity

Start: 2019-01-08End: 2022-05-01Updated: 2023-12-04

A Research Study About Weight Loss and Treatment Patterns With the Use of Saxenda® in Adults in Real-life Settings in Switzerland

CompletedNCT05153590

Novo Nordisk A/SObesity or Overweight

Start: 2021-12-03End: 2022-04-15Updated: 2022-11-17

Related Papers

A randomized phase I study of <scp>BI</scp> 1820237, a novel neuropeptide Y receptor type 2 agonist, alone or in combination with low‐dose liraglutide in otherwise healthy men with overweight or obesity

Diabetes Obesity and Metabolism2024-10-077 citations